UPLC‐MS/MS‐Network Pharmacology and Experimental Validation Reveal Active Components of Ficus tikoua for Ameliorating Liver Fibrosis
Chemistry & Biodiversity · 2026-04 · 23 (4)
DOI: 10.1002/cbdv.71191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 09.04.2026. Verfasst von Shi-Ying Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine & School of Pharmaceutical Sciences, Guizh…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Ficus, Plant Extracts. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Scientific Research Foundation for Innovative Talent of Guizhou Province, Engineering Research Center for the Prevention and Treatment of Chronic Diseases by Authentic Medicinal Materials, Guizhou Provincial Department of Education.
Abstract (Originalsprache)
Ficus tikoua is a medicinal plant traditionally used to treat jaundice and inflammatory‐related diseases. However, the antihepatic fibrosis activity of F. tikoua and its active constituents remain unclear. In this study, a 75% ethanol extract of F. tikoua (FT‐D12) was prepared and evaluated for antihepatic fibrosis effects using both in vitro and in vivo models. FT‐D12 dose‐dependently decreased the expression of fibrosis markers (FN, Collagen I, α‐SMA). In mice, it significantly lowered serum levels of AST, ALT, HYP, hepatic levels of PC‐III, COL IV, HA, and protein expression of α‐SMA and FN. UPLC‐MS/MS analysis elucidated 39 components in FT‐D12, including 30 flavonoids. Network pharmacology screening highlighted apigenin‐7‐ O ‐glucoside, quercetin, icariin, syringetin‐3‐ O ‐glucoside, rutin, isorhamnetin‐3‐ O ‐glucoside, and kievitone as potential antifibrotic candidates. Quercetin showed the strongest inhibitory effect on Collagen I and FN. Further investigation suggested its antifibrotic mechanism may involve modulation of the EGFR‐AKT pathway. These findings provide insight into the anti‐hepatic fibrosis properties of F. tikoua .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine & School of Pharmaceutical Sciences, Guizhou Medical University, Guian New District, Guizhou, China.
- Engineering Research Center For the Prevention and Treatment of Chronic Diseases By Authentic Medicinal Materials, Guizhou Provincial Department of Education, Guian New District, Guizhou, China.
Förderung
- Scientific Research Foundation for Innovative Talent of Guizhou Province
- Engineering Research Center for the Prevention and Treatment of Chronic Diseases by Authentic Medicinal Materials, Guizhou Provincial Department of Education
Zitieren
APA
Xu, S. Y., Luo, Y., Liu, X. F., Ling-Ling, Y., Zhu, Q. F., Ao, J. L., Liao, S. G., He, X., & Xu, G. B. (2026). UPLC‐MS/MS‐Network Pharmacology and Experimental Validation Reveal Active Components of Ficus tikoua for Ameliorating Liver Fibrosis. Chemistry & Biodiversity, 23(4). https://doi.org/10.1002/cbdv.71191
Vancouver
Xu SY, Luo Y, Liu XF, Ling-Ling Y, Zhu QF, Ao JL, et al. UPLC‐MS/MS‐Network Pharmacology and Experimental Validation Reveal Active Components of Ficus tikoua for Ameliorating Liver Fibrosis. Chemistry & Biodiversity. 2026;23(4). doi:10.1002/cbdv.71191
BibTeX
@article{Xu2026,
author = {Xu, Shi-Ying and Luo, Yan and Liu, Xing-Fu and Ling-Ling, Yu and Zhu, Qin-Feng and Ao, Jun-Li and Liao, Shang-Gao and He, Xun and Xu, Guo-Bo},
title = {UPLC‐MS/MS‐Network Pharmacology and Experimental Validation Reveal Active Components of Ficus tikoua for Ameliorating Liver Fibrosis},
journal = {Chemistry & Biodiversity},
year = {2026},
volume = {23},
number = {4},
doi = {10.1002/cbdv.71191}
}
EUVIMED